ArticleClinical kidney journal2026
Higher blood flow rates in anticoagulation-free CRRT improve circuit survival and clinical outcome.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Regional Citrate Anticoagulation Versus No Anticoagulation During Continuous Renal Replacement Therapy in Critically Ill Patients at High Risk of Bleeding: A Meta-analysis of Randomized Controlled Trials.Advances in therapy · 2026Pooled it
- Nafamostat mesylate versus low-molecular-weight heparin during continuous renal replacement therapy in critically Ill adults: a single-center retrospective cohort study.BMC nephrology · 2026Article
- Regional citrate anticoagulation for renal replacement therapy during venovenous ECMO: A randomized crossover pilot study.Annals of intensive care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Anticoagulation-free continuous renal replacement therapy (CRRT) is an essential modality for managing patients with a high bleeding risk; however, it confronts significant challenges stemming from a shortened circuit lifespan. Blood flow rate (BFR) has been recognized as a pivotal non-pharmacological determinant influencing circuit longevity. This retrospective cohort study aimed to systematically evaluate whether elevating BFR to 250 ml/min could enhance CRRT circuit survival compared with the conventional 200 ml/min in anticoagulation-free settings. Methods: We conducted a retrospective analysis of patients receiving anticoagulation-free CRRT from seven intensive care units at West China Hospital of Sichuan University between September 2023 and June 2024. The primary outcome was circuit lifespan, defined as the duration from CRRT initiation to termination due to clotting or other causes. Protective and risk factors were assessed using univariate and multivariate Cox proportional hazards regression. Secondary outcomes included the proportion of circuits achieving predefined lifespans and patient clinical outcomes. Results: Among 128 patients using 241 CRRT circuits (median age: 57 years; 74.27% male), circuits were stratified by BFR: 200 ml/min ( Conclusion: A BFR of 250 ml/min significantly improved circuit survival in anticoagulation-free CRRT compared to 200 ml/min, likely mediated by TMP reduction. Moreover, patients receiving 250 ml/min BFR exhibited lower in-hospital mortality. Our results support adopting a higher BFR to optimize CRRT efficacy in anticoagulation-free settings. Larger-scale prospective trials are needed to validate the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.